Leqembi
Lecanemab, sold under the brand name Leqembi, is a monoclonal antibody medication used for the treatment of mild Alzheimer's disease. Lecanemab is an amyloid beta-directed antibody. It is given via intravenous infusion or subcutaneous injection. In clinical trials, it demonstrated small or no clinically significant efficacy in Alzheimer's disease. The most common side effects of lecanemab include headache, infusion-related reactions, and amyloid-related imaging abnormalities, a side effect known to occur with the class of antibodies targeting amyloid. Lecanemab was jointly developed by Eisai, Biogen, and Bioarctic.
Beyond's analysis on Leqembi
- — Eisai’s subcutaneous Leqembi data signal a user‑friendly alternative that could widen the Alzheimer’s drug market and boost partner BioArctic’s revenues
- — Leqembi’s subcutaneous autoinjector shows comparable efficacy and safety to IV form, potentially widening patient access
Recent news mentioning Leqembi
- — First patient treated with Leqembi® (lecanemab) in Sweden
- — First patient treated with Leqembi® (lecanemab) in Sweden
- — Leqembi® Pen subcutaneous formulation approved in Japan
- — Leqembi® Pen subcutaneous formulation approved in Japan
- — LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer’s Disease
- — Canada's Drug Agency issues final positive recommendation supporting public reimbursement of Leqembi®
- — Canada's Drug Agency issues final positive recommendation supporting public reimbursement of Leqembi®